Forum Financial Management LP purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 982 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nuveen Asset Management LLC lifted its holdings in Alnylam Pharmaceuticals by 5,486.1% during the third quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock valued at $3,321,309,000 after purchasing an additional 16,296,223 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Alnylam Pharmaceuticals by 1.2% during the first quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock valued at $1,768,291,000 after purchasing an additional 126,373 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Alnylam Pharmaceuticals by 3.0% during the second quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock valued at $1,020,524,000 after purchasing an additional 202,916 shares in the last quarter. State Street Corp lifted its holdings in Alnylam Pharmaceuticals by 2.7% during the second quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock valued at $435,925,000 after purchasing an additional 79,369 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Alnylam Pharmaceuticals by 8.8% during the first quarter. Invesco Ltd. now owns 968,755 shares of the biopharmaceutical company’s stock valued at $158,187,000 after purchasing an additional 78,665 shares in the last quarter.
Insider Buying and Selling
In other news, EVP Indrani Lall Franchini sold 1,675 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total transaction of $378,566.75. Following the completion of the sale, the executive vice president now directly owns 3,500 shares in the company, valued at $791,035. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CMO Pushkal Garg sold 18,072 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, March 3rd. The stock was sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the completion of the sale, the chief marketing officer now directly owns 4,345 shares in the company, valued at $869,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Indrani Lall Franchini sold 1,675 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, February 2nd. The stock was sold at an average price of $226.01, for a total value of $378,566.75. Following the sale, the executive vice president now owns 3,500 shares of the company’s stock, valued at $791,035. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.
Analyst Ratings Changes
Alnylam Pharmaceuticals Stock Up 2.7 %
Shares of ALNY opened at $200.32 on Monday. The company has a market cap of $24.87 billion, a PE ratio of -21.56 and a beta of 0.49. The business has a fifty day moving average of $205.69 and a 200 day moving average of $211.91. Alnylam Pharmaceuticals, Inc. has a 52-week low of $117.58 and a 52-week high of $242.97. The company has a quick ratio of 3.34, a current ratio of 3.51 and a debt-to-equity ratio of 3.85.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.13) by $0.45. The company had revenue of $335.04 million during the quarter, compared to the consensus estimate of $312.45 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 109.04%. Alnylam Pharmaceuticals’s revenue was up 29.6% on a year-over-year basis. During the same period last year, the company earned ($2.16) earnings per share. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.93 EPS for the current year.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.
Featured Articles
- Get a free copy of the StockNews.com research report on Alnylam Pharmaceuticals (ALNY)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
